NCT07721961招募中3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Clinical Trial of MI078 Capsules for the Treatment of Patients With Postpartum Depression
Nanjing Minova Pharmaceutical Co., Ltd.36 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2026年7月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 36
- 主要终点
- Change from baseline in HAM-D17 total score
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled trial consisting of an experimental drug group and a placebo group, each enrolling 100 participants. The objective of this study is to assess the efficacy and safety of MI078 capsules for the treatment of postpartum depression.
详细描述
This study is designed as a multicenter, randomized, double-blind, placebo-controlled parallel-group trial. It plans to enroll two groups - one receiving the investigational drug and the other receiving placebo - with 100 participants per group. The study includes a screening period (Day -14 to Day -1), a treatment period (Days 1 to 4), and a follow-up period (Days 5 to 31). Eligible participants will be randomized in a 1:1 ratio and will take the study drug for a total of 3 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients aged 18-45 years (inclusive) with a body mass index (BMI) of 18.5-37.0 kg/m² (inclusive).
- •Based on the investigator's clinical evaluation, the participant meets the diagnostic criteria for Major Depressive Disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by clinical assessment and the Mini-International Neuropsychiatric Interview (M.I.N.I.), with onset of depression between gestational week 28 and 4 weeks postpartum (inclusive).
- •Within 12 months postpartum at baseline.
- •Total score ≥26 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at both screening and baseline.
- •Understand and voluntarily participate in this trial, agree to comply with all study requirements, and provide written informed consent prior to any study-specific procedures.
- •Able to communicate well with the investigator, willing and able to comply with lifestyle restrictions or requirements specified in the protocol, and capable of completing the trial as required.
排除标准
- •Currently meeting diagnostic criteria for other DSM-5 psychiatric disorders, as assessed by the investigator.
- •History of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
- •Reduction in HAM-D17 total score from screening to baseline ≥25%.
- •Presence of suicidal ideation/intent, or HAM-D17 Item 3 (suicide) score >3, or a "yes" response to Item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation in the past 6 months at baseline, or a history of suicidal behavior within 1 year.
- •Meeting diagnostic criteria for treatment-resistant depression.
- •Continuous use of therapeutic doses of antidepressants for more than 14 days during the current episode.
- •Discontinuation of psychotropic medications for less than 5 half-lives prior to the first dose of study drug.
- •Need for concomitant use of other psychoactive drugs during the treatment period, including antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics (excluding non-benzodiazepines).
- •Discontinuation of strong CYP3A4 inducers or inhibitors for less than 5 half-lives prior to the first dose of study drug.
- •Receipt of systematic psychotherapy (e.g., interpersonal therapy, psychodynamic therapy, cognitive-behavioral therapy) or psychiatric-related acupuncture within 1 week prior to the first dose, or planned receipt of such treatments during the trial.
- •Receipt of other physical treatments for psychiatric disorders (e.g., modified electroconvulsive therapy, transcranial magnetic stimulation, psychiatric-related laser therapy, vagus nerve stimulation, deep brain stimulation, light therapy) within 1 month prior to screening.
- •Presence of severe or unstable cardiovascular, hepatic, renal, hematological, endocrine (e.g., uncontrolled hyper- or hypothyroidism), neurological (e.g., epilepsy, Parkinson's disease, multiple sclerosis, Huntington's disease, history of seizure disorder [except single febrile seizure in childhood]), gastrointestinal (e.g., history of gastrointestinal disease or surgery that may interfere with drug absorption, distribution, metabolism, or excretion), or other systemic or organ diseases, as judged by the investigator.
- •History of malignancy within 1 year prior to screening.
- •Participation in another drug trial within 3 months prior to screening, or participation in a medical device trial within 1 month prior to screening (defined as having received investigational drug or device treatment).
- •Major surgery (excluding cesarean section) within 1 month prior to screening, or planned surgery during the trial period.
- •History of hypersensitivity (allergy to at least 2 substances) or known allergy to progesterone.
- •Positive pregnancy test at screening or baseline (for participants who are 4 weeks postpartum, a positive result requires retesting), or unwillingness to use effective contraception throughout the trial and for at least 3 months after the last dose of study drug, or plans for oocyte donation during this period.
- •Clinically significant abnormal 12-lead electrocardiogram (ECG) or laboratory findings at screening or baseline that, in the investigator's opinion, may affect the trial, including but not limited to alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2× upper limit of normal (ULN), or serum creatinine >1.5× ULN.
- •Currently breastfeeding and unwilling to discontinue breastfeeding during the treatment period and for 7 days after the last dose.
- •Any physical/psychological illness or condition that, in the investigator's opinion, may increase the risk of the trial, affect compliance with the protocol, or interfere with the completion of the study, or any other condition that the investigator deems unsuitable for participation in this trial.
结局指标
主要结局
Change from baseline in HAM-D17 total score
时间窗: up to day 31
The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss. The total score ranges from 0 to 52, with higher scores indicating more severe depression.
次要结局
- Change from baseline in the CGI-S score(up to day 31)
- HAM-D17 response(up to day 31)
- HAM-D17 remission(up to day 31)
- Clinical Global Impression - Improvement (CGI-I) scale positive response(up to day 31)
- Change from baseline in MADRS total score(up to day 31)
- Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) total score(up to day 31)
- Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score(up to day 31)
研究者
研究点 (36)
Loading locations...
相似试验
招募中
2 期
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal SurgeryNCT07311369Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.40
招募中
3 期
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoVitiligoNCT07682506Minghui Pharmaceutical (Hangzhou) Ltd405
招募中
3 期
Efavirenz for the Treatment of Creutzfeldt-Jakob DiseaseNCT07482085Xuanwu Hospital, Beijing246
招募中
2/3 期
Clinical Study on HTGF-122105 Capsule in participants with sleeplessnessCTRI/2025/01/078942Himalaya Wellness Company (HWC)100
招募中
不适用
A Clinical Study on Shatavari Capsules for the treatment of Menopausal Symptoms in women.CTRI/2025/11/096876MotherSoul Private Limited66